Progyny, Inc. (PGNY) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
↓
16.00
↓-78% vs avg
5yr avg: 74.14
30Y Low21.3·High56.9
P/FCF
↓
7.99
↓-86% vs avg
5yr avg: 58.68
30Y Low9.5·High119.4
P/B Ratio
↓
3.24
↓-63% vs avg
5yr avg: 8.69
30Y Low3.9·High25.2
ROE
↓
12.5%
↑-20% vs avg
5yr avg: 15.6%
30Y Low-116%·High33%
Debt/EBITDA
↑
0.27
↓-5% vs avg
5yr avg: 0.28
30Y Low0.3·High0.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PGNY Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Progyny, Inc. trades at 28.8x earnings, 54% below its 5-year average of 62.0x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 30%. On a free-cash-flow basis, the stock trades at 8.0x P/FCF, 86% below the 5-year average of 58.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.5B | $2.3B | $1.6B | $3.7B | $3.1B | $5.1B | $4.2B | $2.3B | — | — |
| Enterprise Value | $1.4B | $2.2B | $1.5B | $3.7B | $3.0B | $5.0B | $4.1B | $2.2B | — | — |
| P/E Ratio → | 28.77 | 39.51 | 30.26 | 59.97 | 103.83 | 76.29 | 90.19 | — | — | — |
| P/S Ratio | 1.19 | 1.78 | 1.41 | 3.44 | 3.96 | 10.09 | 12.18 | 9.99 | — | — |
| P/B Ratio | 3.24 | 4.45 | 3.90 | 6.76 | 8.26 | 20.07 | 25.15 | 20.08 | — | — |
| P/FCF | 7.99 | 11.98 | 9.48 | 20.21 | 40.36 | 211.35 | 119.40 | — | — | — |
| P/OCF | 7.29 | 10.93 | 9.19 | 19.82 | 38.73 | 194.07 | 115.98 | — | — | — |
P/E links to full P/E history page with 30-year chart
PGNY EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Progyny, Inc.'s enterprise value stands at 16.0x EBITDA, 78% below its 5-year average of 74.1x. The Healthcare sector median is 14.1x, placing the stock at a 13% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.71 | 1.29 | 3.37 | 3.81 | 9.93 | 12.00 | 9.64 | — | — |
| EV / EBITDA | 16.00 | 24.49 | 21.29 | 56.85 | 120.33 | 147.74 | 403.57 | 187.44 | — | — |
| EV / EBIT | 16.93 | 23.15 | 22.29 | 58.94 | 128.58 | 153.69 | 495.71 | 228.76 | — | — |
| EV / FCF | — | 11.52 | 8.66 | 19.79 | 38.90 | 207.89 | 117.68 | — | — | — |
PGNY Profitability
Margins and return-on-capital ratios measuring operating efficiency
Progyny, Inc. earns an operating margin of 6.6%. ROE of 12.5% is modest. ROIC of 18.1% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 23.6% | 23.6% | 21.7% | 21.9% | 21.3% | 22.4% | 20.3% | 19.8% | 18.4% | 15.2% |
| Operating Margin | 6.6% | 6.6% | 5.8% | 5.7% | 3.0% | 6.5% | 2.4% | 4.2% | -3.3% | -22.7% |
| Net Profit Margin | 4.5% | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% | 13.5% | -3.7% | 0.6% | -25.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.5% | 12.5% | 11.1% | 13.3% | 9.7% | 31.4% | 33.0% | -13.7% | 6.1% | -116.5% |
| ROA | 8.7% | 8.7% | 8.0% | 9.5% | 6.7% | 21.5% | 23.0% | -8.9% | 1.7% | -35.6% |
| ROIC | 18.1% | 18.1% | 13.4% | 12.6% | 8.1% | 17.6% | 8.9% | 32.2% | -23.1% | -73.8% |
| ROCE | 17.4% | 17.4% | 13.4% | 13.0% | 7.3% | 14.9% | 5.7% | 15.4% | -24.4% | -64.0% |
PGNY Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Progyny, Inc. carries a Debt/EBITDA ratio of 0.3x, which is very conservative (92% below the sector average of 3.3x). The company holds a net cash position — cash of $112M exceeds total debt of $24M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.05 | 0.04 | 0.02 | 0.03 | 0.06 | — | 0.02 | 0.49 |
| Debt / EBITDA | 0.27 | 0.27 | 0.27 | 0.30 | 0.31 | 0.26 | 0.93 | — | — | — |
| Net Debt / Equity | — | -0.17 | -0.34 | -0.14 | -0.30 | -0.33 | -0.36 | -0.70 | 0.01 | 0.05 |
| Net Debt / EBITDA | -0.98 | -0.98 | -2.03 | -1.21 | -4.51 | -2.46 | -5.93 | -6.81 | — | — |
| Debt / FCF | — | -0.46 | -0.82 | -0.42 | -1.46 | -3.46 | -1.73 | — | 0.07 | — |
| Interest Coverage | — | — | — | — | — | — | — | 166.84 | -6.95 | -14.87 |
Net cash position: cash ($112M) exceeds total debt ($24M)
PGNY Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Progyny, Inc.'s current ratio of 2.73x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.44x to 2.73x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.73 | 2.73 | 2.80 | 3.44 | 2.72 | 2.62 | 2.45 | 3.66 | 0.81 | 0.94 |
| Quick Ratio | 2.73 | 2.73 | 2.80 | 3.44 | 2.72 | 2.62 | 2.45 | 3.66 | 0.81 | 0.94 |
| Cash Ratio | 1.53 | 1.53 | 1.35 | 2.00 | 1.19 | 1.21 | 1.41 | 2.22 | 0.00 | 0.26 |
| Asset Turnover | — | 1.74 | 1.92 | 1.44 | 1.45 | 1.40 | 1.36 | 1.53 | 2.55 | 1.39 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 62.39 | 73.59 | 81.10 | 111.35 | 98.10 | 80.08 | 74.78 | 80.77 | 85.44 |
PGNY Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Progyny, Inc. returns 5.3% to shareholders annually primarily through share buybacks. The earnings yield of 3.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.5% | 2.5% | 3.3% | 1.7% | 1.0% | 1.3% | 1.1% | — | — | — |
| FCF Yield | 12.5% | 8.3% | 10.5% | 4.9% | 2.5% | 0.5% | 0.8% | — | — | — |
| Buyback Yield | 5.3% | 3.6% | 18.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 5.3% | 3.6% | 18.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $89M | $95M | $101M | $100M | $100M | $99M | $84M | $82M | $6M |
Peer Comparison
Compare PGNY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PGNYYou | $2B | 28.8 | 16.0 | 8.0 | 23.6% | 6.6% | 12.5% | 18.1% | 0.3 |
 HIMS | $7B | 52.7 | 44.5 | 93.8 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 LFST | $3B | 368.0 | 34.8 | 25.9 | 28.5% | 1.8% | 0.7% | 1.2% | 2.4 |
 GDRX | $881M | 30.1 | 3.5 | 5.4 | 82.1% | 13.4% | 4.5% | 13.0% | 0.3 |
 CVS | $111B | 62.5 | 13.1 | 14.3 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 CI | $74B | 12.7 | 8.3 | 8.9 | 9.5% | 3.3% | 14.3% | 10.4% | 2.7 |
 UNH | $333B | 27.8 | 16.6 | 20.7 | 18.5% | 4.2% | 11.8% | 9.2% | 3.4 |
 ELV | $81B | 14.9 | 10.9 | 25.6 | 25.6% | 4.1% | 13.3% | 9.1% | 3.4 |
 HUM | $30B | 25.0 | 16.8 | 78.9 | 14.5% | 1.1% | 7.0% | 4.1% | 5.7 |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 NTRA | $30B | -140.6 | — | 427.2 | 60.3% | -13.1% | -19.4% | -33.3% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See PGNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PGNY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PGNY vs HIMS
Side-by-side business, growth, and profitability comparison vs Hims & Hers Health, Inc..
Start ComparisonPGNY — Frequently Asked Questions
Quick answers to the most common questions about buying PGNY stock.
What is Progyny, Inc.'s P/E ratio?
Progyny, Inc.'s current P/E ratio is 28.8x. The historical average is 66.7x.
What is Progyny, Inc.'s EV/EBITDA?
Progyny, Inc.'s current EV/EBITDA is 16.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 34.2x.
What is Progyny, Inc.'s ROE?
Progyny, Inc.'s return on equity (ROE) is 12.5%. The historical average is -1.4%.
Is PGNY stock overvalued?
Based on historical data, Progyny, Inc. is trading at a P/E of 28.8x. Compare with industry peers and growth rates for a complete picture.
What are Progyny, Inc.'s profit margins?
Progyny, Inc. has 23.6% gross margin and 6.6% operating margin.
How much debt does Progyny, Inc. have?
Progyny, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.